Methanobactin - ArborMed
Alternative Names: ARBM-101; Methanobactin-SB2Latest Information Update: 29 Dec 2023
At a glance
- Originator Helmholtz Zentrum Munchen; Iowa State University; University of Michigan; University of Wisconsin System
- Developer ArborMed
- Class Peptides
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatolenticular degeneration
Most Recent Events
- 10 Nov 2023 Pharmacodynamics data from preclinical studies in Hepatolenticular degeneration presented at the74th Annual Meeting of the American Association for the Study of Liver Diseases 2023 (AASLD-2023)
- 21 Jun 2023 Pharmacodynamics data from preclinical studies in Hepatolenticular degeneration presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
- 09 Jan 2023 ArborMed plans for GLP-tox study in 4Q 2022 (ArborMed website 2023)